healthcare innovation summit 2016

Global Hospital & Healthcare Management




Aug 25th
  • Bookmark and Share
  • Login
  • Sign up
    Fields marked with an asterisk (*) are required.
    Name: *
    Username: *
    E-mail: *
    Password: *
    Verify Password: *
    Company name: *
  • Search
Text size
  • Increase font size
  • Default font size
  • Decrease font size
HHM Global
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it to e-mail and schedule a conversation with the editors at the conference.

Featured Articles
  • Pause
  • Previous
  • Next
Philips showcases full suite of cardiology at ESC Congress 2016 (22.08.2016)
Royal Philips announced its presence at the ESC Congress 2016, showcasing its latest in advanced integrated cardiology solutions with a focus on prevention, diagnosis and treatment. Philips will spotlight multiple modalities to address the needs of a growing and aging population with a personalized and cost effective approach to cardiovascular care, featuring: IntelliSpace Cardiovascular, Dynamic Coronary Roadmap, EPIQ with HeartModel Anatomical Intelligence (AI) as well as Philips Volcano IVUS and iFR/FFR technologies. 

Visitors to the Philips booth (#E4-N100) will experience Philips holistic approach to cardiovascular care, featuring its integrated cardiology software, innovative solutions and best-in-class services approach to connect people, technologies and care protocols across the entire health continuum. From intravascular imaging, ultrasound, healthcare IT and advanced software applications, to physiology image guided interventional technologies and Personal Health Solutions for better heart health, Philips is providing a customized integrated approach to deliver enhanced workflow for the entire clinical team.
 “Cardiovascular disease is the leading cause of death and accounts for more costs than any other chronic illness,”said Bert van Meurs, Business Leader of Image Guided Therapy for Philips. “At Philips, we believe every heart is unique and every patient deserves an individual approach to their health. To this end, we’re providing clinicians with the tools they need to enable efficient and effective clinical decision making and deliver personalized care to each one of their patients. As health systems continue to move toward value-based care, we’re committed to transforming workflow for first time right diagnosis, increasing productivity and improving outcomes for cardiology patients at the point of care.”
During this year’s Congress, Philips and its customer partners will host a Satellite Symposium on Ultrasound featuring leading echo experts sharing their latest experience related to Anatomical Intelligence and Peri-interventional Imaging followed by an interactive panel discussion. Hands-on tutorials on topics including next-generation point-of-care testing enabling rapid clinical decision making, precision guided technologies in the interventional lab, and Anatomical Intelligence within ultrasound, will also be presented. Throughout the event, Philips will also host a daily series of short presentations on solutions and technologies enabling personalized heart care, taking place in the Forum section of the booth. For the full schedule of short talks, please click here.
Visitors to the Philips booth at the ESC Congress 2016 will also have access to the company’s recently launched AlluraClarity Clinically Proven platform, introducing the scientific community to 18 comparative peer-reviewed studies with 3,840 patients. Clinical data demonstrates the ability of Philips’ AlluraClarity to provide equivalent image quality for a full range of clinical procedures at low X-ray dose levels.
Diagnosis and Treatment
Philips will demonstrate its advanced solutions delivering diagnostic confidence and decision-making through every step of the cardiology patient journey, including:
HeartModel AI –  premier Anatomical Intelligence Ultrasound (AIUS) application - part of a suite of tools and technologies available on Philips’ EPIQ Ultrasound system that brings advanced automated quantification, 3D views, robust reproducibility and significant time-savings to echocardiography
IntelliSpace Cardiovascular – next generation image and information integrated software solution gives access to the full range of images and includes a cardiac history timeline to provide a comprehensive overview of the patients’ care along the health continuum
IntelliSpace Portal 7.0 – advanced cardiology informatics data sharing, analytics and visualization platform to help clinicians diagnose patients and communicate across modalities, with one efficient, automated, and guided workflow
Minicare 1-20 Acute – on the spot handheld point-of-care blood testing that speeds up clinical cardiac assessment providing lab comparable Troponin results within minutes.Affinity 70 Ultrasound – offers a powerful combination of performance and workflow for quick, confident diagnosis
Also showcased in the Philips booth are advanced technologies driving navigation for appropriate treatment paths, including:
EchoNavigator – fuses live 3D TEE and X-ray in real time to provide image guidance in the 3D space, supporting physicians in complex structural heart procedures for the appropriate treatment path, enabling better patient and cost effective care
IVUS (intravascular ultrasound)  – provides detailed and accurate measurements of the vessel and a wide range of clinical studies has been shown to help ensure accurate stent expansion 
iFR Scout – pullback technology reveals the physiologic profile of the entire vessel and is optimized to assess serial lesions and diffuse coronary disease enabling physicians to make informed treatment decisions
Dynamic Coronary Roadmap – provides live 3D image guidance for navigating vascular structures by overlaying real-time 2D fluoroscopy images and a 3D reconstruction of the vessel tree acquired with the 3D-RA feature of your Allura X-ray system or from a previous CT/MR scan*
StentBoost Live – a tool for stent visualization in the coronary arteries*
HeartNavigator – provides immersive user experience and automated tasks to simplify planning, measurement, device selection, and choice of X-ray viewing angle for TAVI, LAA, Mitral and other SHD procedures
3D Room Planner -  a digital tool that enables modality specialists to closely work together in creating a lively experience and understanding of the future OR in a 3D simulation

Edwards SAPIEN 3 Transcatheter Heart Valve Receives Expanded Indication From FDA (17.08.2016)
Edwards Lifesciences Corporation the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced U.S. Food and Drug Administration (FDA) approval to expand use of the Edwards SAPIEN 3 transcatheter heart valve for the treatment of patients suffering from severe, symptomatic aortic stenosis who have been determined by a Heart Team to be at intermediate risk for open-heart surgery. The SAPIEN 3 valve is the first transcatheter aortic valve replacement (TAVR) therapy to obtain this indication in the United States.
"The SAPIEN 3 valve has set a new standard for performance and patient outcomes with aortic valve replacement," said Vinod Thourani, M.D., co-director of Emory Heart and Vascular Center's Structural Heart and Valve Center and professor of cardiothoracic surgery at Emory University School of Medicine. "The clinical outcomes of 1.1 percent mortality and 1.0 percent disabling stroke at 30 days in this intermediate-risk population treated with the SAPIEN 3 valve are changing the paradigm of how we treat patients with aortic stenosis."
Thourani is the co-principal investigator of the SAPIEN 3 valve study. 
"The intermediate-risk approval of the SAPIEN 3 valve is a major milestone, since it provides a less-invasive therapy that has demonstrated better outcomes for aortic valve patients, and is supported by the largest and rigorous comparative body of evidence for the treatment of aortic stenosis," said Larry L. Wood, Edwards' corporate vice president, transcatheter heart valves.
The SAPIEN 3 valve intermediate-risk approval was based on data from a cohort of the PARTNER II Trial, which studied 2,005 intermediate-risk patients at 51 sites in the United States and Canada. The study demonstrated that patients treated with the SAPIEN 3 valve experienced clinically significant improvements for the composite primary endpoint of mortality, stroke and moderate or severe aortic regurgitation at one year as compared to those treated with surgery.  The data were presented in April at the American College of Cardiology's 65th Annual Scientific Session and simultaneously published in The Lancet.
The expanded intermediate-risk indication granted by the FDA enables Heart Teams to treat patients with the SAPIEN 3 valve who they determine to have a predicted risk of surgical mortality of greater than or equal to 3 percent at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical co-morbidities unmeasured by the STS risk calculator.  
The SAPIEN 3 valve builds on Edwards' decades of experience in the development of tissue heart valves, and the proven benefits of the Edwards SAPIEN valves. The SAPIEN 3 valve was approved by the FDA in June 2015 for the treatment of patients with severe, symptomatic aortic stenosis who are at high-risk for open heart surgery.  
About Edwards Lifesciences
Edwards Lifesciences, based in Irvine, Calif., is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Driven by a passion to help patients, the company collaborates with the world's leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives. For more information, and follow us on Twitter @EdwardsLifesci.
Contact Information :
Heather Chambers,
949-250-5070, or 
David K. Erickson,
both of Edwards Lifesciences Corporation

Apollo Hospitals to invest Rs 1,200 crore in oncology unit (03.08.2016)
The investment will be made into Apollo Cancer Institute (ACI), said Preetha Reddy, Executive Vice-Chairperson, Apollo Hospitals Group, .

Apollo Hospitals will be investing Rs 1,200 crore over the next three years in its oncology division which will now be an independent entity. The investment will be made into Apollo Cancer Institute (ACI), said Preetha Reddy, Executive Vice-Chairperson, Apollo Hospitals Group, here. In a press release, Reddy said the Group has re-branded the Cancer Hospitals in its chain of hospitals as ACI, which currently has nine centres with 700 super-specialist oncologists. 

"Though ACI will be an independent entity from now on, accounting could be separated after March 31. However, we will report on this in six months," she said. "Cancer currently contributes 20 to 22 per cent to the Hospital Division. 

In the next three years, an investment of Rs 1,200 crore will be made into oncology division. We are looking at 12 to 15 per cent volume increase in one year's time for cancer. The next Apollo Cancer Institute will be at Mumbai and we will further add centres," she said. The ACI is focused on three pronged strategy of prevention, early detection and treatment, Reddy said. 

This amalgamation of all cancer hospitals will help in sharing of knowledge, treatment modalities and best practices across the network for optimum treatment, uniformity of care, precision and best treatment outcomes, Reddy said. Treatment planning will be same across ACI centres, she added.




Himss 2016

E-newsletter - latest issue of Hospital & Healthcare Management Newsletter
Please click here to view this newsletter online
Click here to subscribe to our newsletter

M2M communication resulting in new and exciting possibilities in healthcare

The world appears to have shrunk into a virtual ball. People are getting connected through devices; machines are getting connected; and today, even homes are getting connected. Everything in the world is getting connected.


Effective patient engagement leads hospitals to higher margins & healthy future

Recent Accenture research suggests that hospitals that offer a superior patient experience tend to have 50 percent higher margins than their peers . Hospitals that deliver a superior experience have the opportunity to create happy and healthy patients, as well as a healthy financial future......


Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2017

The board of directors of Medtronic plc approved the fiscal year 2017 second quarter cash dividend of $0.43 per ordinary share, representing a 13 percent increase over the prior year.  This quarterly declaration is consistent with the dividend a...

Philips and SURFsara team up to provide hospitals with ‘Big Data’ research services in the Cloud for

Collaboration combines Philips’ expertise in health informatics and SURFsara’s capabilities in high performance supercomputing infrastructuresVia online portal combined cloud-based services will facilitate multicenter life sciences resear...

Case Study: IBM - i3ARCHIVE

Customeri3ARCHIVEDeployment CountryPennsylvania - USAIndustryHealthcare, Life SciencesSolutionBusiness-to-Business, Business-to-Consumer, Business Performance Transformation, Business Resiliency, Content Management, Data Warehouse, Database Managemen...

Merck to Develop Next-Generation Purification Processes with International Vaccine Institute

Merck, a leading science and technology company, has entered a research agreement with the International Vaccine Institute (IVI) of Seoul, South Korea to help develop more robust, scalable vaccine manufacturing processes. Merck will provide funding a...
GlobeNewswire: Latest search results from Industry: (Health Care) AND Tag: (HEALTH) | Keyword(s): hospital
Contains the last 10 releases
  • ScarX announces approval for trial of first clinically-promising scar reduction cream

    TORONTO, Aug. 18, 2016 (GLOBE NEWSWIRE) -- Toronto-based ScarX Therapeutics (ScarX) has received approval from Health Canada to begin a Phase I clinical trial of its SCX-001 nefopam cream, a first-of-its-kind topical treatment developed to significantly reduce surgical scarring.

    Applied immediately after surgical wound...

  • Access Scientific Debuts POWERWAND XL Midline Catheter

    SAN DIEGO, July 19, 2016 (GLOBE NEWSWIRE) -- Access Scientific has introduced the POWERWAND™ XL, a companion to the POWERWAND ALL-IN-ONE. The new POWERWAND XL is designed specifically for clinicians who prefer to use a component-based, over-wire insertion technique similar to the Modified Seldinger Technique (MST) they currently use. The...

  • ENT and Allergy Associates, LLP(R) Adds a Lauded Veteran ENT to its West Side Story

    TARRYTOWN, N.Y., July 12, 2016 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA) prides itself on offering its 80,000 monthly ear, nose, throat, allergy and audiology patients the services of first rate quality physicians. And when it identifies a potential new addition with a proven track record of superb...

  • YMCA and athenahealth Partner on Community Integrated Health

    CHICAGO and WATERTOWN, Mass., July 08, 2016 (GLOBE NEWSWIRE) -- YMCA of the USA (Y-USA), a leading community-based nonprofit committed to improving the nation?s health, and athenahealth, Inc. (NASDAQ:ATHN), a leading provider of network-enabled services and mobile applications for healthcare...

  • Landmark Health Hosts Grand Opening

    ALBANY, N.Y., June 24, 2016 (GLOBE NEWSWIRE) -- House calls are making a comeback thanks to a new local business that is transforming care for thousands of local patients. Landmark Health is providing in-home, concierge-level care to Capital Regions residents with multiple chronic conditions.

    Landmark clinicians are on-call 24-7...

Medical Fair Asia 2016
Subscribe for E-Newsletter


Aug 2016 - PDF | e-book

Technology and Analytics are the key elements playing important role in many aspects of the healthcare delivery system.

With this in mind, we introduce the latest edition of Hospital & Healthcare Management Magazine - Vol 5 Issue 4 your one-stop resource that hepls you stay up to date with the issues that matters the most.

View Previous Issues:
May'16 | Feb'16 | Aug'15 | Feb'15 | Aug'14 | Feb'14 | June'13 | Feb.'13 | Aug.'12 | Apr.'12 | Dec.'11 | Aug.'11 | >> 

Product Showcase


Online Medical Records Vault by Sajix Inc

Sajix Inc come up with this unique and revolutionary offering- OMR Vault - iHelix’s Personal H...


Flowline Worlds only Servo controlled High Frequency Oscillatory Ventilator DRAGONFLY

WORLDS Only SERVO Controlled High Frequency Oscillatory Ventilator (HFOV) Model DRAGONFLY Features: ...

Feedback Form
Real Time Web Analytics